Home › Trials › NCT06292845
Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Using fluorescent imaging agents to improve tumor removal during surgery

Official title: Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents

Run by Erasmus Medical Center · NCT06292845 · Data updated 2026-11-12

This study is testing a new way to help surgeons see and remove all of the cancer during surgery by using special fluorescent dyes that highlight tumor tissue.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment200 (estimated)
SponsorErasmus Medical Center
Academic / other
Locations1 site (Rotterdam, South Holland)
StatusRecruiting
StartedJanuary 16, 2024
Main results expectedDecember 1, 2027
Study endsDecember 1, 2027
Registry record updatedSeptember 11, 2026
Trial IDNCT06292845 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with biopsy-proven solid tumors who are scheduled for surgery at the Erasmus Medical Center.

Probably not a fit

Patients whose surgical procedures are terminated or who do not have fresh specimens available will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of topically applied fluorescent imaging agents on freshly resected human solid tumor specimens to identify tumor tissue and assess resection margins. The goal is to enhance the accuracy of surgical excisions by providing real-time feedback on the presence of tumor cells at the margins. By improving the detection of tumor-positive margins, the study aims to reduce the need for additional treatments that can lead to increased morbidity and healthcare costs. The approach does not interfere with standard clinical care and is designed to complement existing surgical techniques.

Why it matters

Potential benefit: If successful, this technique could lead to more complete tumor resections and better patient outcomes by reducing the rates of inadequate surgical margins.

How similar studies have gone: While fluorescence imaging is an emerging technique, this specific application for real-time margin assessment in solid tumors is novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Patients with a biopsy-proven solid tumor, scheduled for surgery at the Erasmus Medical Center.
2. Signed and dated informed consent obtained before any study-related procedure is performed.

Exclusion Criteria:

1. Terminated surgical procedure.
2. No fresh specimen available.
3. Participation in a clinical trial for which the patient receives another fluorophore perioperatively.

Where it's running

  • Erasmus University Medical Center
    Rotterdam, South Holland, Netherlands     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Solid Tumor, Adult 76Erasmus Medical Center 125
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.